Several complement inhibitors have been developed and are under investigation for their potential in treating neurological disorders:
1. Eculizumab: This drug inhibits the complement protein C5 and is already in use for treating neuromyelitis optica. It has shown promise in reducing the frequency of relapses. 2. Ravulizumab: A long-acting version of eculizumab, providing more extended protection against complement-mediated damage. 3. C1 Inhibitors: These inhibitors act on the C1 component of the complement system and are being explored for their potential in treating conditions like hereditary angioedema and potentially in neurological contexts.
